Abstract
Cancer is a class of diseases characterized by out-of-control cell growth, which are the building blocks of the body. Imatinib, known by its brand-Gleevec, is a type of biological therapy called tyrosine kinase inhibitor (TKI) which, a chemical messenger, is protein that cells use to signal each other to grow and thus pro-motes cancer. Structure-based method includes inverse docking was used to anticipate of most probable protein targets of Imatinib from tyrosine kinase protein using in silico approaches. Seven tyrosine kinase proteins have been preferred for the docking evaluation. In which, re-docking was performed to evaluate the docking validation. Among them, Crystal structure of native c-Kit kinase in an auto inhibited conformation (PDB: 1T46), LCK bound to imatinib (PDB: 2PL0), P38 in complex with Imatinib/Transferase (PDB: 3HEC), and ABL kinase in complex with Imatinib and a fragment (FRAG1) in the myristate pocket (PDB: 3MS9) and were most potential protein targets for the Imatinib ligand which computed by both of these schemes. These validated proteins have been selected for the virtual library screening of 1500 natural compounds from NPACT database. Luxenchalcone, Schweinfurthin and Sanggenon M were the best docked ligands and have chosen for the understanding the plausible mechanism at molecular level by implying the molecular dynamics simulations to determine the conformational changes and stabilization which reveals the potency of these ligands towards the treatment of cancer treatment.